Related Experiment Video
Updated: Apr 26, 2026

04:47
Author Spotlight: Learning Systematic Bronchoscopy in a Simulation-Base Setting
Published on: June 23, 2023
4.1K
Practical issues in autofluorescence bronchoscopy with Storz D Light bronchoscope
1Department of Respiratory Medicine, Princess Alexandra Hospital, Brisbane, Australia.
Photodiagnosis and Photodynamic Therapy
|July 23, 2014
Summary
Storz Dlight autofluorescence bronchoscopy aids in detecting dysplasia and CIS lesions during lung cancer screening. However, fluorescence abnormalities can be misleading, with a 56% positive predictive value in this study.
Area of Science:
- Pulmonology
- Oncology
- Medical Imaging
Background:
- Autofluorescence bronchoscopy (AFB) is an endoscopic technique used for early detection of lung cancer.
- The Storz Dlight system offers advancements in autofluorescence imaging.
- Accurate interpretation of fluorescence abnormalities is crucial for effective diagnosis.
Purpose of the Study:
- To evaluate the practical aspects and diagnostic yield of Storz Dlight autofluorescence bronchoscopy.
- To identify causes of false positive findings in autofluorescence imaging.
- To determine the positive predictive value of significant fluorescence abnormalities.
Main Methods:
- A series of 73 patients underwent Storz Dlight autofluorescence bronchoscopy.
- 80 biopsies were performed based on fluorescence findings.
- Analysis included correlation of fluorescence abnormalities with histopathological results.
Main Results:
- 23 out of 80 biopsies showed moderate dysplasia or carcinoma in situ (CIS) lesions.
- Identified causes of false positive fluorescence included suction trauma, mucus, and bronchial spur morphology.
- The positive predictive value for significant fluorescence abnormalities was 56%.
Conclusions:
- Storz Dlight autofluorescence bronchoscopy can detect significant dysplasia and CIS.
- Careful interpretation is needed to avoid false positives due to factors like mucus and trauma.
- The highest diagnostic yield was observed in patients with a history of head and neck cancer.

